ClinicalTrials.gg
CompletedNCT06641037Updated Apr 1, 2025

A Study of LY3866288 in Healthy Participants

A Phase 1 interventional study of LY3866288 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 9 weeks including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be of nonchildbearing potential or of and agree to use
  • Males must either be infertile via bilateral orchiectomy or vasectomized at least 90 days prior to screening with proper documentation
  • (BMI) between 18.5 and 32.0 kilogram per square meter (kg/m²)
  • In good general health, determined by no findings from medical history, physical examination, 12 lead (ECGs), vital signs measurements, or clinical laboratory evaluations at screening and/or check-in as assessed by the investigator (or designee)

Exclusion criteria

Exclusion Criteria:

  • Females only: Are lactating or pregnant
  • Any history or presence of disease(s), deemed :

    • Dermatological disease
    • Liver disease
    • Metabolic disease, including congenital nonhemolytic hyperbilirubinemia (e.g., Gilbert syndrome)
    • Gastrointestinal disease, including peptic ulcer disease, active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug, or gastric reduction surgery. Note: participants with a history of appendectomy and/or inguinal hernia repairs will be acceptable
    • Biliary disease, including cholecystectomy
    • Cancer within the past 5 years (except localized basal cell, squamous, or in situ cancer of the skin)
    • History or current evidence of ophthalmic disorder, such as central serous retinopathy or retinal vein occlusion, active wet age-related macular degeneration, diabetic retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
    • Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to first dose, or 12-lead abnormalities that are clinically significant at screening
  • History of alcohol and/or drug abuse within 2 years prior to screening
  • Have been on a diet incompatible with the on-study diet, in the opinion of the investigator (or designee), and as confirmed by the sponsor, within the 30 days prior to Day 1 and throughout
  • Use of tobacco, smoking cessation products, products containing nicotine, or e-cigarettes (nicotine and non-nicotine) within 90 days prior to screening and throughout
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    LY3866288 Cohort 1 (High-Fat Meal)

    LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort

    Drug: LY3866288

  • Experimental
    LY3866288 Cohort 2 (Low-Fat Meal)

    LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort

    Drug: LY3866288

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288

    PK: AUC From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288

    Time frame: Baseline to Study Completion (Up to 3 Weeks)

  2. PK: AUC Extrapolated to Infinity of LY3866288

    PK: AUC Extrapolated to Infinity of LY3866288

    Time frame: Baseline to Study Completion (Up to 3 Weeks)

  3. PK: Maximum Concentration (Cmax) of LY3866288

    PK: Cmax of LY3866288

    Time frame: Baseline to Study Completion (Up to 3 Weeks)

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 15, 2024
StartActual
Oct 17, 2024
Primary completionActual
Dec 2, 2024
CompletionActual
Dec 2, 2024
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06641037
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 17, 2024
Primary completion
Dec 2, 2024
Completion
Dec 2, 2024
Last update
Apr 1, 2025

Study contacts

Contact Lilly at 1-800-LillyRx (1-800-545-5979)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepugratinib

Start the discussion